Multinational pharma companies operating in India will be the major losers under the new Drug Price Control Order (DPCO). Nineteen of their top selling medicines have been included in the list of 30 molecules finalised by the government to be placed under price control.
The final list has also been approved by the law ministry.
MNC pharma companies to be affected by the new DPCO include Hoechst Marion, Novartis, Knoll Pharma, Glaxo, German Remedies, USV, Fullford India and Wyeth Lederele.
Hoechst Marion will be one of the most affected as four of its medicines (which have the largest market shares in each molecule) will now come under the price control. Out of these, two are new additions. Hoechst’s turnover to the tune of Rs 150 crore (as on March 2001) will now be under price control .
Similarly, three medicines each of Novartis India and Knoll India will now fall under the price control. Novartis’ drugs under price control are Diclofenac, Calcium Carbonate and Xylometazoline having a total turnover of over Rs 111 crore. Knoll’s three drugs -Ibuprofen, Insulin and Phenytoin (largest selling drugs in that category) have a total turnover of Rs 184 crore.
The final list of 30 molecules includes 15 new additions while the balance 15 will be carried forward from DPCO 1995. The 15 new molecules are: Diclofenac, Metformin, Norfloxacin, Calcium Carbonate, Bisacodyl, Cefotaxime, Cefuroxime, Chlo-rpheneiramine, Glibenclamide, Povidone Iodine, Norethistero-ne, phenobarbitone, Phenytoin, Promethazine, Rabies Antigen and Xylometazoline.
The carried forward molecules are: